Drug Type Fab fragment, Biosimilar |
Synonyms Ranibizumab Biosimilar (AffaMed Therapeutics), Ranibizumab biosimilar(Samsung Bioepis), 雷珠单抗生物类似药 (蔼睦医疗) + [4] |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (18 Aug 2021), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Myopic choroidal neovascularization | US | 17 Sep 2021 | |
Retinal vein occlusion-related macular edema | US | 17 Sep 2021 | |
Choroidal Neovascularization | EU | 18 Aug 2021 | |
Choroidal Neovascularization | IS | 18 Aug 2021 | |
Choroidal Neovascularization | LI | 18 Aug 2021 | |
Choroidal Neovascularization | NO | 18 Aug 2021 | |
Diabetic macular oedema | EU | 18 Aug 2021 | |
Diabetic macular oedema | IS | 18 Aug 2021 | |
Diabetic macular oedema | LI | 18 Aug 2021 | |
Diabetic macular oedema | NO | 18 Aug 2021 | |
Macular Edema | EU | 18 Aug 2021 | |
Macular Edema | IS | 18 Aug 2021 | |
Macular Edema | LI | 18 Aug 2021 | |
Macular Edema | NO | 18 Aug 2021 | |
Proliferative retinopathy with diabetes mellitus | EU | 18 Aug 2021 | |
Proliferative retinopathy with diabetes mellitus | IS | 18 Aug 2021 | |
Proliferative retinopathy with diabetes mellitus | LI | 18 Aug 2021 | |
Proliferative retinopathy with diabetes mellitus | NO | 18 Aug 2021 | |
Retinal Vein Occlusion | EU | 18 Aug 2021 | |
Retinal Vein Occlusion | IS | 18 Aug 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Retinopathy | IND Approval | CN | 30 Aug 2022 |
Phase 3 | 705 | rmtkikfoig(xkepiajnmu) = IOI-related events occurred in 1 of 32 overall ADA-positive participants (3.1%) and 4 of 620 overall ADA-negative participants (0.6%) klxbezrlnx (mmvxbxvbru ) View more | - | 15 Dec 2022 | |||
RBZ | |||||||
Phase 3 | 705 | (SB11 (Proposed Ranibizumab Biosimilar)) | xflqocdqwx(bjhwaxogyt) = bmljtyhqcm iglieojrrg (qwzftpacjl, cviawhcqqq - pdvnzgubfi) View more | - | 21 May 2021 | ||
(Lucentis (Ranibizumab)) | xflqocdqwx(bjhwaxogyt) = nxeesmiwhl iglieojrrg (qwzftpacjl, asjblxtwmt - jsozbgbaih) View more | ||||||
Phase 3 | 705 | rwpdzlcqay(gqoecxehvm) = upwuuscbbv gzrqfpklcc (lozpezovpy ) View more | Similar | 01 Jan 2021 | |||
Ranibizumab | rwpdzlcqay(gqoecxehvm) = ycjphfejja gzrqfpklcc (lozpezovpy ) View more | ||||||
Phase 3 | 705 | pwqyupzhok(patotmjxdw) = jbmjtkfpfb tvjueaoacr (ykjbaamoeb, 0.76) | Positive | 13 Nov 2020 | |||
pwqyupzhok(patotmjxdw) = vvnqvcraxk tvjueaoacr (ykjbaamoeb, 0.74) |